Teligent — IGI Laboratories — Investor Presentation (July 2012)
14 slides from Teligent's investor presentation, Jul 9, 2012
Slide 1: IGI Laboratories, Inc. Investor Presentation
VazE> LABORATORIES IGI Laboratories, Inc. Investor Presentation July 2012 Charles Moore, President and CEO Jenniffer Collins, Chief Financial Officer
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by IGI Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and i
Slide 3: Company Overview
Company Overview Our mission — to be a leading developer and manufacturer of generic topical prescription drug products Dermatology focus — Pharmaceutical, OTC, cosmetics and skin care — “Niche” $3 billion sub market of the overall pharmaceutical market — Only three major players, due to more signif
Slide 4: Key Facts
Key Facts Symbol - IG $1.02 || $0.85- 1.34 Debt (3/31/12) Cash (3/31/12) Revenue (TTM at March 31, 2012) December 31st isnerAmper, LLP
Slide 5: Management Team
Management Team (Charlie Moore, President and CEO 25+ yrs at Altana, (later Nycomed), filed 50 ANDAs in 10 years Jenniffer Collins, CFO 20+ yrs of accounting, finance, including \PriceWaterhouseCoopers INadya Lawrence, Exec. VP of Sales land Marketing [15+ yrs at IGI, Inc. VP of Operations [David Pe
Slide 6: The Prescription Topical Generic Opportunity
The Prescription Topical Generic Opportunity Topicals are a “niche” higher margin market with barriers to entry: — Cost of Bioequivalence — API Availability — Formulation Challenges Total US Topical Market 2011: *$11 Billion Concentrated Markets with less competition than traditional tabs and capsul
Slide 7: IGI in the Pharmaceutical Market
IGI in the Pharmaceutical Market ¢ Three Pathways: * Developing our own ANDAs — 8 applications submitted — Expect to submit 4 to 6 ANDAs with the FDA each year — First two approvals anticipated in the next 6 to 9 months ¢ Authorized Generics — IGI has been granted marketing rights to authorized gene
Slide 8: IGI's ANDA Pipeline
IGI’s ANDA Pipeline Targeting Markets With Sales Over $200M 8 applications currently submitted — Total Market Size of approximately $80 Million based on 2011 IMS data Another 6 ANDAs currently under development, expected late 2012 and 2013 submission — Total Market Size of approximately $120 Million
Slide 9: Built The Foundation for Sustainable Growth
Built The Foundation for Sustainable Growth Stabilized the Contract Services Business — Transformed business to generate cash flow to fund our development efforts — Created significant operating leverage — Improved margins with the addition of more pharmaceutical customers Expanded Product Developme
Slide 10: Stabilized Contract Services
Stabilized Contract Services Contract Formulation Contract Manufacturing PD Revenue ($000) Sales ($Million) 10 8 6 4 2 0 2009 2010 2011 2009 «20102011 * Developed more than 20 customer * Sales doubled from 2009 to 2011 formulations in 2011 * Signed a 3 year contract extension with largest * Grown fr
Slide 11: Our Facilities
Our Facilities FDA registered, cGMP compliant manufacturing site Manufacturing capabilities for topical prescription, OTC and cosmetic products — Liquids- Creams- Lotions- Gels- Ointments Full service analytical laboratories, including microbiology Proprietary encapsulation technology We currently o
Slide 12: Balance Sheet
Balance Sheet a ‘e LABORATORIES Balance Sheet as of: Dec-31-2010 Dec-31-2011 Mar-31-2012 Currency usD usD usD ASSETS Total Cash & ST Investments 5.116 2.914 2.188 Accounts Receivable ois 1.208 1.567 Other Receivables 0.234 0.239 0.009 Total Receivables 1.049 1.447 1.576 Inventory 0.816 1.195 1.199 P
Slide 13: Income Statement
Income Statement a ‘e LABORATORIES ‘om 12months 3 monthsQ1 3monthsQ2 3monthsQ3_ 3monthsQ4 12 months 3 monthsQ1 {in $USD, millions) Dec-31-2010 Mar31-2011 Jun-30-2011 Sep-302011 Dec31-2011 Dec-31-2011 Mar-312012 Revenue 6.077 1574 2.014 2.087 2.082 IS 1.832 Other Revenue 0.017 : 0.01 0.026 0.013 0.05
Slide 14: Investor Highlight Summary
Investor Highlight Summary More than doubled top line revenue in 2 years Improved margins 10 basis points from 2010 to 2011, and trend will continue with the manufacturing of more and more pharmaceutical products We have stream lined our operations, and the contract services business is now profitab